Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Pemetrexed/Docetaxel in Advanced NSCLC
NCT03566576Phase 1Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Dose Limiting Toxicity and Maximum Tolerated Dose. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03566576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03566576.